39 completed. 39 Phase 2, 7 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 39 | Completed 39 |
| Phase 1 | 7 | Completed 7 |
| Phase 3 | 3 | Completed 3 |
Follow Tinnitus: new trials by email Literature Review of Tinnitus trials Research Report on Tinnitus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acute Nicotine Gum and Tinnitus Loudness in Non-Smoking Adults Nicotine polacrilex gum 4 mg, Placebo gum - Tinnitus, Chronic Subjective Tinnitus | Phase 1 / Phase 2 | Completed | San Diego State University | 29 | 2026-03-25 | 2026-10-16 |
| Blinding and Adverse Effects of Ultrasonic Vagus Nerve Stimulation (U-VNS) Ultrasound Vagus Nerve Stimulation (U-VNS), Sham U-VNS - U-VNS, Sham U-VNS | Phase 1 / Phase 2 | Completed | University of Nottingham | 20 | 2024-12-10 | 2025-07-29 |
| An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus Brexanolone - Tinnitus | Phase 2 | Completed | Supernus Pharmaceuticals, Inc. | 10 | 2023-05-10 | 2025-09-15 |
| The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial incobotulinum toxin A, Placebo-Saline - Tinnitus | Phase 2 | Completed | University of Minnesota | 41 | 2023-01-01 | 2026-10-27 |
| OTO-313 in Subjects With Unilateral Subjective Tinnitus OTO-313, Placebo - Subjective Tinnitus | Phase 2 | Completed | Otonomy, Inc. | 153 | 2021-03-22 | 2023-01-06 |
| Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus Ketamine Hydrochloride in saline - Tinnitus | Phase 2 | Completed | New York State Psychiatric Institute | 42 | 2019-09-01 | 2026-03-25 |
| OTO-313 in Subjects With Subjective Tinnitus OTO-313, Placebo - Tinnitus, Subjective | Phase 1 / Phase 2 | Completed | Otonomy, Inc. | 43 | 2019-04-04 | 2022-12-23 |
| A Study on the Effectiveness of Antioxidant Supplementation in Tinnitus Antioxidants, Placebo - Tinnitus | Phase 2 | Completed | National and Kapodistrian University of Athens | 70 | 2019-01-10 | 2019-11-13 |
| SPI-1005 for the Treatment of Patients With Meniere's Disease 200mg SPI-1005 BID, 400mg SPI-1005 BID, Placebo - Meniere's Disease | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 149 | 2017-09-28 | 2023-09-18 |
| SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2 - Ototoxicity | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 35 | 2017-07-21 | 2026-07-16 |
| Study to Evaluate SPI-1005 in Adults With Meniere's Disease SPI-1005 - Meniere's Disease | Phase 1 / Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 40 | 2015-12-01 | 2026-06-29 |
| Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo AUT00063, Placebo - Tinnitus, Subjective | Phase 2 | Completed | Autifony Therapeutics Limited | 91 | 2014-10-01 | 2016-03-31 |
| Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus Sulodexide, Placebo - Tinnitus, Subjective | Phase 2 | Completed | St Joseph University, Beirut, Lebanon | 126 | 2014-08-01 | 2017-09-14 |
| Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. AZD4017, Placebo - Idiopathic Intracranial Hypertension | Phase 2 | Completed | University of Birmingham | 31 | 2014-04-25 | 2021-10-27 |
| OTO-104 for the Treatment of Meniere's Disease OTO-104, Placebo - Meniere's Disease | Phase 2 | Completed | Otonomy, Inc. | 154 | 2013-11-01 | 2015-09-03 |
| Evaluation of the CR Neuromodulation Treatment for Tinnitus CR Neuromodulation, Tinnitus masking - Tinnitus | Phase 2 / Phase 3 | Completed | Nottingham University Hospitals NHS Trust | 100 | 2012-08-01 | 2016-08-22 |
| Treatment of Chronic Bothersome Tinnitus Using Cognitive Training and D-cycloserine Cognitive Training - Tinnitus | Phase 2 | Completed | Washington University School of Medicine | 37 | 2012-01-01 | 2013-05-23 |
| Gameplay as a Source of Intrinsic Motivation in a Randomized Controlled Trial of Auditory Training for Tinnitus reactive auditory training, Interactive auditory training - Tinnitus | Phase 1 / Phase 2 | Completed | Nottingham University Hospitals NHS Trust | 60 | 2011-08-01 | 2016-11-04 |
| Transcranial Magnetic Stimulation for Tinnitus repetitive transcranial magnetic stimulation (rTMS), placebo rTMS - Tinnitus | Phase 1 / Phase 2 | Completed | VA Office of Research and Development | 70 | 2011-03-01 | 2017-03-29 |
| Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus AM-101 0.81 mg/mL, Placebo - Tinnitus | Phase 2 | Completed | Auris Medical, Inc. | 82 | 2011-02-01 | 2015-01-26 |
Showing 20 of 39. Sign in to see all of them.
Hearing Loss (7) · Vertigo (4) · Meniere Disease (3) · Headache (2) · Hearing Loss, Noise-Induced (2) · Obesity (2) · Papilledema (2) · Pseudotumor Cerebri (2) · Anxiety Disorders (1) · Blindness (1) · Bronchiolitis Obliterans Syndrome (1) · Cystic Fibrosis (1) · Depression (1) · Diplopia (1)
Ear Diseases (39) · Nervous System Diseases (39) · Neurologic Manifestations (39) · Otorhinolaryngologic Diseases (39) · Pathological Conditions, Signs and Symptoms (39) · Sensation Disorders (39) · Signs and Symptoms (39) · Hearing Disorders (38) · Labyrinth Diseases (4) · Vestibular Diseases (4) · Endolymphatic Hydrops (3) · Behavior (2) · Body Weight (2) · Brain Diseases (2) · Central Nervous System Diseases (2)
Transcranial Magnetic Stimulation (3) · ebselen (3) · PDCD5 protein, rat (2) · 2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid (1) · AUT00063 (1) · Acetaminophen (1) · Acetazolamide (1) · Antioxidants (1) · Aspirin (1) · Codeine (1) · Cognitive Behavioral Therapy (1) · Cognitive Training (1) · Counseling (1) · Gabapentin (1) · Ibuprofen (1)
Otonomy, Inc. (3) · Sound Pharmaceuticals, Incorporated (3) · Washington University School of Medicine (3) · Nottingham University Hospitals NHS Trust (2) · US Department of Veterans Affairs (2) · University of Iowa (2) · Auris Medical AG (1) · Auris Medical, Inc. (1) · Autifony Therapeutics Limited (1) · Bayer (1) · GlaxoSmithKline (1) · Islamic Azad University of Mashhad (1) · Merz Pharmaceuticals GmbH (1) · National and Kapodistrian University of Athens (1) · New York State Psychiatric Institute (1)
United States (22) · Germany (8) · United Kingdom (7) · Poland (2) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Greece (1) · Lebanon (1) · Netherlands (1)
Jonathan Kil, MD (3) · Alexandra Sinclair, MbChb PhD (1) · Carl LeBel, PhD (1) · Carol Bauer, MD (1) · Christian Plewnia, M.D. (1) · Colleen G Le Prell, PhD (1) · David McAlpine, PhD (1) · Deborah A Hall, PhD (1) · Deborah Hall, Professor (1) · Derek J Hoare, PhD (1) · Diana Martinez (1) · Elias Eter, MD (1) · Emmanuel Cuny, MD (1)
PMID 18193350, PMID 18600443, PMID 19045972, PMID 19698089, PMID 21223542, PMID 21422304, PMID 21751942, PMID 21974483, PMID 22122960, PMID 22168528, PMID 22217183, PMID 23598691, PMID 23599075, PMID 24756302, PMID 24756514, PMID 24781936, PMID 24975234, PMID 25017670, PMID 25215617, PMID 25356570, PMID 25370510, PMID 25370513, PMID 25470623, PMID 26024112, PMID 26181507, PMID 26335066, PMID 26618282, PMID 26778344, PMID 26934136, PMID 27694262, PMID 28130349, PMID 28183355, PMID 28492874, PMID 28923789, PMID 30939361, PMID 32483557, PMID 33098644, PMID 33637230, PMID 34510123, PMID 35326273, PMID 36240084, PMID 37740611, PMID 41341514
R01DC005972 (1), R01DC009095 (1), U01DC008423 (1), U10EY017281 (1), U10EY017387 (1)